AbbVie’s (ABBV) Skyrizi Gets Nod for Psoriatic Arthritis in EU Posted byZacks Equity Research November 18, 2021 Leave a comment on AbbVie’s (ABBV) Skyrizi Gets Nod for Psoriatic Arthritis in EU AbbVie (ABBV) secures approval in the EU for Skyrizi to treat adult patients with active psoriatic arthritis.